APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
S. 23, the America Invents Act, Section 10, Supplemental Examination H.R. 1249, the American Invents Act, Section 11, Supplemental Examination
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Pharmacy PHA
S. 27, the Preserve Access to Affordable Pharmaceuticals Act Amending Section 505(j)(5)(c)(ii)(I) of the Food, Drug and Cosmetic Act, concerning the ability of generic pharmaceutical manufacturers to file counterclaims seeking the correction of incorrect information submitted to FDA's Orange Book by patent owners or holders of New Drug Applications
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.